Efficacy and Safety of Imatinib in the First Line Chronic
Myeloid Leukemia (CML) Treatment. An Analysis of a
Comprehensive Population-Based Database.

a 2009

Efficacy and Safety of Imatinib in the First Line Chronic Myeloid Leukemia (CML) Treatment. An Analysis of a Comprehensive Population-Based Database.

ŽÁČKOVÁ, Daniela, Hana KLAMOVÁ, Michael DOUBEK, Zdeněk POSPÍŠIL, Dana DVOŘÁKOVÁ et. al.

Basic information

Original name

Efficacy and Safety of Imatinib in the First Line Chronic Myeloid Leukemia (CML) Treatment. An Analysis of a Comprehensive Population-Based Database.

Authors

ŽÁČKOVÁ, Daniela, Hana KLAMOVÁ, Michael DOUBEK, Zdeněk POSPÍŠIL, Dana DVOŘÁKOVÁ, Tomáš JURČEK, Jana MORAVCOVÁ, Kateřina MACHOVÁ POLÁKOVÁ, Jana RULCOVÁ, Blanka DOBEŠOVÁ, Jana RYŠAVÁ, Petr CETKOVSKÝ, Filip RÁZGA and Jiří MAYER

Edition

Haematologica/The Hematology Journal. 2009;94(s2):346. 2009

Other information

Language

English

Type of outcome

Conference abstract

Field of Study

30200 3.2 Clinical medicine

Confidentiality degree

is not subject to a state or trade secret

Organization unit

Faculty of Medicine

UT WoS

000266931900857

Přehled o publikaci